Kazakhstan Pharmaceuticals & Healthcare Report Q1 2013: New Research Report Available At Fast Market Research

Recently published research from Business Monitor International, "Kazakhstan Pharmaceuticals & Healthcare Report Q1 2013", is now available at Fast Market Research

by Bill Thompson

(WireNews+Co) - Boston, MA - 08 February 2013

BMI View: Kazakhstan's pharmaceutical market remains the most accessible, transparent and, from a legislative point of view, progressive in Central Asia. In terms of market size, its potential is limited by its relatively small population (15mn) and logistical challenges. In the short term, Kazakhstan's market development is driven by a balanced policy of import substitution and integration into regional (Customs Union) and global (World Trade Organisation) systems. Over the longer term, the country could leverage its favourable business environment and regional ties to supply neighbouring states, such as Uzbekistan, Kyrgyzstan, Turkmenistan and Tajikistan, all of which have growing populations and lack domestic production capacity. The country's government is in the middle of implementing an industrial development policy for pharmaceuticals and three of the top five producers - Chimpharm, Nobel and Global Pharm - are now controlled by foreign investors. The primary threat to the industry and foreign investment is the spectre of political instability (and consequent economic instability) that may occur when President Nursultan Nararbayev, who has led the country since Soviet times, leaves the scene. This is especially relevant as no heir is yet in place.

View Full Report Details and Table of Contents (http://www.fastmr.com/prod/529413_kazakhstan_pharmaceuticals_healthcare_report_q1.aspx?afid=201) (http://www.fastmr.com/prod/529413_kazakhstan_pharmaceuticals_healthcare_report_q1.aspx?afid=201)

Headline Expenditure Projections

- Pharmaceuticals: KZT218.1bn (US$1.46bn) in 2012 to KZT245.4bn (US$1.65bn) in 2013; up 12.5% in local currency terms and 12.8% in US dollar terms. Forecast adjusted up slightly due to updated exchange rate forecasts.
- Healthcare: KZT1,165.2 (US$7.82bn) in 2012 to KZT1,330.3bn (US$8.95bn) in 2013; up 14.2% in local currency terms and 14.5% in US dollar terms. Forecast adjusted up slightly due to updated exchange rate forecasts.
- Medical Devices: KZT93.35bn (US$630mn) in 2012 to KZR102.3bn (US$690mn) in 2012; up 9.5% in local currency terms and 9.8% in US dollar terms. Forecast adjusted up due to new data and updated exchange rate forecasts.

Risk/Reward Rating: Kazakhstan ranks 14th out of 20 in BMI's Risk/Reward Ratings for Emerging Europe this quarter. The market's key attractions include a liberalising regulatory system and positive outlook for WTO accession in 2013, as well as strong economic growth and the growing pace of state investment in healthcare. Downsides include a small population, infrastructure challenges and the reliance of the economy on commodities, which poses nearly permanent exchange rate risks and exposure to volatility. The country's largest single risk, however, is the reliance of the political system on President Nazarbayev, who has presided over two decades of rapid development but also hindered the development of effective governance that will outlast him.

Fast Market Research (http://www.fastmr.com?afid=201) is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.